Alnylam Pharmaceuticals | ALNY - Current Liabilities


Alnylam Pharmaceuticals reported $1.47B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Incyte USD 1.52B 176.44M Dec/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
Moderna USD 1.99B 306M Dec/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 32B 286M Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 28.35B 9.32B Dec/2025
Sarepta Therapeutics USD 921.42M 1.48M Sep/2025
Takeda JPY 2.61T 470.53B Dec/2025
Tectonic Therapeutic USD 9.37M 1.99M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025
Xencor USD 86.48M 9.6M Sep/2025